Capricor Therap Cmn (CAPR) 3.70 $CAPR
Capricor Therapeutics to Present at JMP Life Sciences Conference
PR Newswire - Wed Jun 22, 5:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 JMP Life Sciences Conference on June 22, 2016 at 9:00 am EDT in New York City.
CAPR: 3.70 (-0.03)
Capricor Therapeutics to Present at 2016 BIO International Convention
PR Newswire - Tue May 31, 6:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 BIO International Convention on June 6, 2016 at 4:00 p.m. PDT in San Francisco.
CAPR: 3.70 (-0.03)
Capricor reports 1Q loss
Automated Insights - Thu May 12, 3:50PM CDT
BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $4.3 million in its first quarter.
CAPR: 3.70 (-0.03)
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the first quarter ended March 31, 2016 as well as a business update.
CAPR: 3.70 (-0.03)
Investor Calendar Invites You to the Capricor Therapeutics First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016
ACCESSWIRE - Wed May 11, 3:11PM CDT
LOS ANGELES, CA / ACCESSWIRE / May 11, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 12, 2016 at 4:30 PM Eastern Time.
CAPR: 3.70 (-0.03)
Akers Biosciences (AKER) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:52AM CDT
Akers Biosciences Inc (AKER) is expected to report first-quarter 2016 results on May 12.
CAPR: 3.70 (-0.03), STAA: 6.84 (+0.08), AKER: 3.04 (+0.23), VBLT: 4.02 (unch)
Capricor Therapeutics to Hold First Quarter 2016 Business Update and Financial Results Conference Call on May 12, 2016 at 4:30 p.m. EDT
PR Newswire - Thu May 05, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss first quarter 2016 financial results and recent business highlights at 4:30 p.m. EDT, May 12, 2016.
CAPR: 3.70 (-0.03)
Cardiovascular (CSII) Narrows Loss in Q3, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:36AM CDT
Cardiovascular Systems Inc. (CSII) reported third-quarter fiscal 2016 adjusted net loss per share of 31 cents.
CAPR: 3.70 (-0.03), CSII: 19.61 (+0.31), BAX: 48.02 (-0.20), CRDC: 2.35 (-0.15)
Abaxis (ABAX) Q4 Earnings Beat Estimates; Dividend Raised
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 9:21AM CDT
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2016 earnings per share (EPS) of 36 cents from continuing operations.
BSX: 24.28 (-0.06), CAPR: 3.70 (-0.03), CSII: 19.61 (+0.31), ABAX: 49.46 (-0.26)
Zimmer Biomet (ZBH) Beats on Q1 Earnings, Margins Drag
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:51AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported first-quarter 2016 adjusted earnings per share (EPS) of $2.00, up 29.9% year over year.
BSX: 24.28 (-0.06), CAPR: 3.70 (-0.03), ZBH: 131.14 (+3.67), BAX: 48.02 (-0.20)
Phibro: Animal Health Grows amid Competition from Generics
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 1:35PM CDT
On Apr 7, 2016, we issued an updated research report on New Jersey-based Phibro Animal Health (PAHC).
CAPR: 3.70 (-0.03), CSII: 19.61 (+0.31), PAHC: 20.63 (-0.26), BAX: 48.02 (-0.20)
Capricor Therapeutics Announces DSMB Recommends Continuation of HOPE-Duchenne Clinical Trial
PR Newswire - Mon Apr 04, 7:30AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that the independent Data Safety Monitoring Board (DSMB) of the Phase I/II HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) clinical trial has completed its pre-specified review of the first patient cohort. Based on the DSMB's recommendation, enrollment in the trial will continue as planned. The HOPE-Duchenne trial is evaluating CAP-1002, Capricor's lead product candidate, in boys with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy.
CAPR: 3.70 (-0.03)
Capricor Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
PR Newswire - Thu Mar 17, 3:00PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the fourth quarter and full year ended December 31, 2015 as well as a business update.
CAPR: 3.70 (-0.03)
Capricor Awarded $3.4 Million Grant from California Institute for Regenerative Medicine
PR Newswire - Thu Mar 17, 11:50AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that the Board of the California Institute for Regenerative Medicine (CIRM) has approved a grant award to Capricor for approximately $3.38 million to support the Company's Phase I/II HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) clinical trial investigating CAP-1002, a cardiac cell therapy, in patients with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy. The award was granted under the CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. Capricor also reported today the completion of enrollment of the pre-specified first patient cohort in the HOPE-Duchenne trial.
CAPR: 3.70 (-0.03)
Investor Calendar Invites You to the Capricor Therapeutics Fourth Quarter 2015 Earnings Conference Call and Webcast Live on Thursday, March 17, 2016
ACCESSWIRE - Wed Mar 16, 3:06PM CDT
LOS ANGELES, CA / ACCESSWIRE / March 16, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the fourth quarter 2015, to be held Thursday, March 17, 2016 at 4:30 PM Eastern Time.
CAPR: 3.70 (-0.03)
Capricor Therapeutics Announces $4 Million Registered Direct Offering
PR Newswire - Tue Mar 15, 7:30AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that it has entered into a Subscription Agreement with certain investors for the purchase and sale of 1,692,151 shares of common stock at a price of $2.40 per share and warrants to purchase up to 846,073 shares of common stock with an exercise price of $4.50 per share. The warrants will be exercisable six months and one day from the date of the closing of the offering and have a term of three years. The gross proceeds of the offering are expected to be approximately $4.1 million, before deduction of placement agent fees and offering expenses payable by Capricor. The closing of the offering is expected to take place on or about March 15, 2016, subject to the satisfaction of customary closing conditions.
CAPR: 3.70 (-0.03)
Capricor Therapeutics to Hold Fourth Quarter 2015 Financial Results and Business Update Conference Call on March 17, 2016 at 4:30 p.m. EDT
PR Newswire - Thu Mar 10, 7:00AM CST
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss fourth quarter 2015 financial results and recent business highlights at 4:30 p.m. EDT, March 17, 2016. The call will discuss recent advancements in the Company's cell therapy program centered on the ALLSTAR and HOPE-Duchenne (DMD) clinical trials, as well as reveal preclinical findings from its exosomes program.
CAPR: 3.70 (-0.03)
Capricor Therapeutics to Present at Upcoming Investor Conferences
PR Newswire - Tue Mar 08, 7:00AM CST
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that management is scheduled to present at two upcoming investor conferences.
CAPR: 3.70 (-0.03)
Capricor Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marban, Ph.D., Chief Executive Officer, is scheduled to present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016 at 9:30 a.m. EST in New York City.
CAPR: 3.70 (-0.03)
Capricor Therapeutics to Present at JMP Life Sciences Conference
PR Newswire - Wed Jun 22, 5:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 JMP Life Sciences Conference on June 22, 2016 at 9:00 am EDT in New York City.
CAPR: 3.70 (-0.03)
Capricor Therapeutics to Present at 2016 BIO International Convention
PR Newswire - Tue May 31, 6:00AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at the 2016 BIO International Convention on June 6, 2016 at 4:00 p.m. PDT in San Francisco.
CAPR: 3.70 (-0.03)
Capricor reports 1Q loss
Automated Insights - Thu May 12, 3:50PM CDT
BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $4.3 million in its first quarter.
CAPR: 3.70 (-0.03)
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 12, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the first quarter ended March 31, 2016 as well as a business update.
CAPR: 3.70 (-0.03)
Investor Calendar Invites You to the Capricor Therapeutics First Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, May 12, 2016
ACCESSWIRE - Wed May 11, 3:11PM CDT
LOS ANGELES, CA / ACCESSWIRE / May 11, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the first quarter 2016, to be held Thursday, May 12, 2016 at 4:30 PM Eastern Time.
CAPR: 3.70 (-0.03)
Akers Biosciences (AKER) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:52AM CDT
Akers Biosciences Inc (AKER) is expected to report first-quarter 2016 results on May 12.
CAPR: 3.70 (-0.03), STAA: 6.84 (+0.08), AKER: 3.04 (+0.23), VBLT: 4.02 (unch)
Capricor Therapeutics to Hold First Quarter 2016 Business Update and Financial Results Conference Call on May 12, 2016 at 4:30 p.m. EDT
PR Newswire - Thu May 05, 3:05PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss first quarter 2016 financial results and recent business highlights at 4:30 p.m. EDT, May 12, 2016.
CAPR: 3.70 (-0.03)
Cardiovascular (CSII) Narrows Loss in Q3, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:36AM CDT
Cardiovascular Systems Inc. (CSII) reported third-quarter fiscal 2016 adjusted net loss per share of 31 cents.
CAPR: 3.70 (-0.03), CSII: 19.61 (+0.31), BAX: 48.02 (-0.20), CRDC: 2.35 (-0.15)
Abaxis (ABAX) Q4 Earnings Beat Estimates; Dividend Raised
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 9:21AM CDT
Abaxis, Inc. (ABAX) reported fourth-quarter fiscal 2016 earnings per share (EPS) of 36 cents from continuing operations.
BSX: 24.28 (-0.06), CAPR: 3.70 (-0.03), CSII: 19.61 (+0.31), ABAX: 49.46 (-0.26)
Zimmer Biomet (ZBH) Beats on Q1 Earnings, Margins Drag
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:51AM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported first-quarter 2016 adjusted earnings per share (EPS) of $2.00, up 29.9% year over year.
BSX: 24.28 (-0.06), CAPR: 3.70 (-0.03), ZBH: 131.14 (+3.67), BAX: 48.02 (-0.20)
Phibro: Animal Health Grows amid Competition from Generics
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 1:35PM CDT
On Apr 7, 2016, we issued an updated research report on New Jersey-based Phibro Animal Health (PAHC).
CAPR: 3.70 (-0.03), CSII: 19.61 (+0.31), PAHC: 20.63 (-0.26), BAX: 48.02 (-0.20)
Capricor Therapeutics Announces DSMB Recommends Continuation of HOPE-Duchenne Clinical Trial
PR Newswire - Mon Apr 04, 7:30AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that the independent Data Safety Monitoring Board (DSMB) of the Phase I/II HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) clinical trial has completed its pre-specified review of the first patient cohort. Based on the DSMB's recommendation, enrollment in the trial will continue as planned. The HOPE-Duchenne trial is evaluating CAP-1002, Capricor's lead product candidate, in boys with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy.
CAPR: 3.70 (-0.03)
Capricor Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
PR Newswire - Thu Mar 17, 3:00PM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today provided financial results for the fourth quarter and full year ended December 31, 2015 as well as a business update.
CAPR: 3.70 (-0.03)
Capricor Awarded $3.4 Million Grant from California Institute for Regenerative Medicine
PR Newswire - Thu Mar 17, 11:50AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that the Board of the California Institute for Regenerative Medicine (CIRM) has approved a grant award to Capricor for approximately $3.38 million to support the Company's Phase I/II HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) clinical trial investigating CAP-1002, a cardiac cell therapy, in patients with Duchenne muscular dystrophy (DMD)-associated cardiomyopathy. The award was granted under the CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. Capricor also reported today the completion of enrollment of the pre-specified first patient cohort in the HOPE-Duchenne trial.
CAPR: 3.70 (-0.03)
Investor Calendar Invites You to the Capricor Therapeutics Fourth Quarter 2015 Earnings Conference Call and Webcast Live on Thursday, March 17, 2016
ACCESSWIRE - Wed Mar 16, 3:06PM CDT
LOS ANGELES, CA / ACCESSWIRE / March 16, 2016 / Capricor Therapeutics, Inc. (NASDAQ: CAPR) will host a conference call and live webcast to discuss the results of the fourth quarter 2015, to be held Thursday, March 17, 2016 at 4:30 PM Eastern Time.
CAPR: 3.70 (-0.03)
Capricor Therapeutics Announces $4 Million Registered Direct Offering
PR Newswire - Tue Mar 15, 7:30AM CDT
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that it has entered into a Subscription Agreement with certain investors for the purchase and sale of 1,692,151 shares of common stock at a price of $2.40 per share and warrants to purchase up to 846,073 shares of common stock with an exercise price of $4.50 per share. The warrants will be exercisable six months and one day from the date of the closing of the offering and have a term of three years. The gross proceeds of the offering are expected to be approximately $4.1 million, before deduction of placement agent fees and offering expenses payable by Capricor. The closing of the offering is expected to take place on or about March 15, 2016, subject to the satisfaction of customary closing conditions.
CAPR: 3.70 (-0.03)
Capricor Therapeutics to Hold Fourth Quarter 2015 Financial Results and Business Update Conference Call on March 17, 2016 at 4:30 p.m. EDT
PR Newswire - Thu Mar 10, 7:00AM CST
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that company management will hold a conference call to discuss fourth quarter 2015 financial results and recent business highlights at 4:30 p.m. EDT, March 17, 2016. The call will discuss recent advancements in the Company's cell therapy program centered on the ALLSTAR and HOPE-Duchenne (DMD) clinical trials, as well as reveal preclinical findings from its exosomes program.
CAPR: 3.70 (-0.03)
Capricor Therapeutics to Present at Upcoming Investor Conferences
PR Newswire - Tue Mar 08, 7:00AM CST
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that management is scheduled to present at two upcoming investor conferences.
CAPR: 3.70 (-0.03)
Capricor Therapeutics to Present at 18th Annual BIO CEO & Investor Conference
PR Newswire - Tue Feb 02, 6:00AM CST
Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced that Linda Marban, Ph.D., Chief Executive Officer, is scheduled to present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016 at 9:30 a.m. EST in New York City.
CAPR: 3.70 (-0.03)
